Science News
from research organizations

Interleukin 17F level and interferon beta response in patients with multiple sclerosis

Date:
June 3, 2013
Source:
The JAMA Network Journals
Summary:
A new study examines the association between IL-17F and treatment response to interferon beta-1b among patients with relapsing-remitting multiple sclerosis.
Share:
       
FULL STORY

A study by Hans-Peter Hartung, M.D., of Heinrich-Heine-Universität, Düsseldoft, Germany, and colleagues examines the association between IL-17F and treatment response to interferon beta-1b among patients with relapsing-remitting multiple sclerosis. (Online First)

Serum samples were analyzed with an immunoassay from 239 randomly selected patients treated with interferon beta-1b, 250 micrograms, for at least 2 years in the Betaferon Efficacy Yielding Outcomes of a New Dose Study. Researchers measured the levels of IL-17F at baseline and month 6, as well as the difference between the IL-17F levels at month 6 and baseline were compared between: (1) patients with less disease activity versus more disease activity; (2) patients with no disease activity versus some disease activity; and (3) responders versus nonresponders.

According to study results,levels of IL-17F measured at baseline and month 6 did not correlate with lack of response to treatment after 2 years using clinical and magnetic resonance imaging (MRI) criteria. Relapses and new lesions on MRI were not associated with pretreatment serum IL-17F levels. When patients with neutralizing antibodies were excluded, the results did not change.

"We found that serum concentrations of IL-17F alone did not predict response to interferon beta-1b therapy in patients with relapsing-remitting multiple sclerosis." The study concludes, "Given the multifaceted pathophysiology associated with disease progression and response to treatment by patients with relapsing-remitting multiple sclerosis, using extreme patient cohorts in combination with immune-based biomarker signatures may actually be the most efficient way of initially identifying response markers."


Story Source:

The above post is reprinted from materials provided by The JAMA Network Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Hans-Peter Hartung et al. Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis. JAMA Neurol, 2013 DOI: 10.1001/.jamaneurol.2013.192

Cite This Page:

The JAMA Network Journals. "Interleukin 17F level and interferon beta response in patients with multiple sclerosis." ScienceDaily. ScienceDaily, 3 June 2013. <www.sciencedaily.com/releases/2013/06/130603164153.htm>.
The JAMA Network Journals. (2013, June 3). Interleukin 17F level and interferon beta response in patients with multiple sclerosis. ScienceDaily. Retrieved September 4, 2015 from www.sciencedaily.com/releases/2013/06/130603164153.htm
The JAMA Network Journals. "Interleukin 17F level and interferon beta response in patients with multiple sclerosis." ScienceDaily. www.sciencedaily.com/releases/2013/06/130603164153.htm (accessed September 4, 2015).

Share This Page: